BoM., CorsinoviL., BrescianiniA.High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis.Angiology.2009; IN PRESS.
2.
RidkerP.M.Clinical application of C-reactive protein for cardiovascular disease detection and prevention.Circulation.2003; 107: 363–369.
3.
PaffenE., DeMaatM.P.C-reactive protein in atherosclerosis: a causal factor?Cardiovasc Res.2006; 71: 30–39.
4.
MillerV.M., RedfieldM.M., McConnellJ.P.Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk.Curr Vasc Pharmacol.2007; 5: 15–25.
5.
RidkerP.M., CushmanM., StampferM.J., TracyR.P., HennekensC.H.Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.Circulation.1998; 97: 425–428.
6.
ShankarA., LiJ., NietoF.J., KleinB.E., KleinR.Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension.Am Heart J.2007; 154: 495–501.
7.
WildmanR.P., MuntnerP., ChenJ.Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002.Am J Cardiol.2005; 96: 1579–1583.
8.
VuJ.D., VuJ.B., PioJ.R.Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease.Am J Cardiol2005; 96: 655–658.
9.
HozawaA., OhmoriK., KuriyamaS.C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project.Hypertens Res.2004; 27: 955–961.
10.
DaskalopoulouS.S., PathmarajahM., KakkosS.K.Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication.Circ J.2008; 72: 441–448.
11.
HultheJ., WikstrandJ., FagebergB.Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study.Clin Sci (Lond).2001; 100: 371–378.
12.
KheraA., de LemosJ.A., PeshockR.M.Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study.Circulation.2006; 113: 38–43.
13.
VainasT., StassenF.R., de GraafR.C-reactive protein in peripheral arterial disease: relation to severity of the disease and future cardiovascular events.J Vasc Surg.2005; 42: 243–251.
14.
TzoulakiI., MurrayG.D., LeeA.J., RumleyA., LoweG.D., FowkesF.G.C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.Circulation.2005; 112: 976–983.
15.
Van Der MeerI.M., De MaatM.P., HakA.E.C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study.Stroke.2002; 33: 2750–2755.
16.
OwensC.D., RidkerP.M., BelkinM.Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery.J Vasc Surg.2007; 45: 2–9.
17.
FatourouE.M., ParaskevasK.I., SeifalianA.M., HamiltonG., MikhailidisD.P.The role of established and emerging risk factors in peripheral vascular graft occlusion.Expert Opin Pharmacother.2007; 8: 901–911.
18.
AbdellaouiA., Al-KhaffafH.C-reactive protein (CRP) as a marker in peripheral vascular disease.Eur J Vasc Endovasc Surg.2007; 34: 18–22.
19.
LiJ.J., FangC.H., JiangH.Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis.Angiology.2004; 55: 479–484.
20.
BarutcuI., SezginA.T., SezginN.Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow.Angiology.2007; 58: 401–407.
21.
OrenH., ErbayA.R., BalciM.Role of novel biomarkers of inflammation in patients with stable coronary heart disease.Angiology.2007; 58: 148–155.
22.
OrenH., ErbayA.R., BalciM., CehreliS.Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients?Angiology.2007; 58: 45–54.
23.
LiangY.J., ShyuK.G., WangB.W.Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.Cardiology.2008; 110: 182–190.
24.
AsherJ., HoustonM.Statins and C-reactive protein levels.J Clin Hypertens (Greenwich).2007; 9: 622–628.
25.
EfthimiadisA.Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?Angiology.2008; 59(2 suppl): 62S–64S.
26.
SchillingerM., ExnerM., MlekuschW.Statin therapy improves cardiovascular outcome of patients with peripheral artery disease.Eur Heart J.2004; 25: 742–748.
27.
TsiaraS., ElisafM., MikhailidisD.P.Early vascular benefits of statin therapy.Curr Med Res Opin.2003; 19: 540–556.
28.
MilionisH.J., RizosE., KostapanosM.Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).Curr Med Res Opin.2006; 22: 1123–1131.
29.
DaskalopoulouS.S., DaskalopoulosM.E., LiapisC.D., MikhailidlsD.P.Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality.Curr Med Chem.2005; 12: 443–452.
30.
AlnaebM.E., AlobaidN., SeifalianA.M., MikhailidisD.P., HamiltonG.Statins and peripheral arterial disease: potential mechanisms and clinical benefits.Ann Vasc Surg.2006; 20: 696–705.
31.
IsmaN., BaraniJ., MattiasonI., LindbladB., GottsäterA.Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia.Angiology.2008; 59: 542–548.
32.
ParaskevasK.I., MikhailidisD.P.C-reactive protein (CRP): more than just an innocent bystander?Curr Med Res Opin.2008; 24: 75–78.
33.
NakouE.S., LiberopoulosE.N., MilionisH.J., ElisafM.S.The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.Curr Vasc Pharmacol.2008; 6: 258–270.
34.
HirschfieldG.M., GallimoreJ.R., KahanM.C.Transgenic human C-reactive protein is not proatherogenic in apolipoprotein-E deficient mice.Proc Natl Acad Sci USA.2005; 102: 8309–8314.
35.
TennentG.A., HutchinsonW.L., KahanM.C.Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.Atherosclerosis.2008; 196: 248–255.
36.
LoweG.D., PepysM.B.C-reactive protein and cardiovascular disease: weighing the evidence.Curr Atheroscler Rep.2006; 8: 421–428.
37.
PitsavosC., PanagiotakosD.B., TzimaN.Diet, exercise and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study.Angiology.2007; 58: 225–233.
38.
PepysM.B.CRP or not CRP? That is the question.Arterioscler Thromb Vasc Biol.2005; 25: 1091–1094.
39.
SucklingK.The continuing complexes of high-density lipoprotein metabolism in drug discovery and development.Expert Opin Ther Targets.2007; 11: 1133–1136.
40.
LudwigR.J., SchonM.P., BoehnckeW.H.P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis.Expert Opin Ther Targets.2007; 11: 1103–1117.
JeyaseelanK., HerathW.B., ArmugamA.MicroRNAs as therapeutic targets in human diseases.Expert Opin Ther Targets.2007; 11: 1119–1129.
44.
ParaskevasK.I., PsathasC., DragiosT.The impact of novel treatment modalities on the therapeutic approach of cardiovascular diseases.Angiology.2009; IN PRESS.
45.
RidkerC.M., CannonC.P., MorrowD., and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein and outcomes after statin therapy.N Engl J Med.2005; 352: 20–28.
46.
RidkerP.M., DanielsonE., FonsecaF.A.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med.2008; 359: 2195–2207.
47.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA.2001; 285: 2486–2497.
48.
TziomalosK., AthyrosV.G., KaragiannisA., MikhailidisD.P.JUPITER: major implications for vascular risk assessment.Curr Med Res Opin.2009; IN PRESS.
